Rheumatoid Arthritis Drug Development Guidelines Reflect New Standards Of Care
Executive Summary
FDA’s new draft guidance seems to offer more flexibility on study duration, but it makes clear that trials lasting longer than 12 weeks should use an active comparator, not placebo.
You may also be interested in...
RA Remission Claim May Be Granted Despite Relapse - FDA Guidance
Rheumatoid arthritis remission indications may be approved even if patients relapse after six months or more of remission, FDA's Feb. 17 final guidance on RA treatments states.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.